Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Rising Dilution
AIAI Summary
MAZE is a well-funded but highly binary clinical-data bet: the 36% UACR reduction in only 12 patients makes late-2026/early-2027 HORIZON confirmation the decisive catalyst, with replicated durable efficacy and clean safety potentially supporting a pivotal APOL1 program while failure could sharply reset valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Rising Dilution
MAZE's strong liquidity and low leverage provide runway, but zero revenue, persistent losses, cash burn, and dilution make it a high-risk, equity-financed investment.
Price Behavior
Key Price Behavior Insights:
- •Lower lows
- •Selling acceleration
- •Oversold momentum
MAZE fell about 22% over the last month to new lows, with a deeply oversold RSI suggesting bounce potential but bearish momentum persisting unless price reclaims $24.60–$24.80.
RSI near 15 indicates an unusually stretched decline and potential technical rebound
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Pipeline advancement
- •Insider selling
Institutional buying and clinical progress support Maze Therapeutics' outlook, though an anomalous ARCH valuation and the CMO's full share sale warrant caution.
Net sentiment is constructive for Maze, but investors should monitor insider activity and verify reported ownership valuations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings